查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球病毒滅活市場增長、未來展望、競爭分析 (2022-2030)
市場調查報告書
商品編碼
1192883

全球病毒滅活市場增長、未來展望、競爭分析 (2022-2030)

Viral Inactivation Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

2021 年全球病毒滅活市場規模預計將達到 5.5 億美元，在 2022-2030 年的預測期內以 12.5% 的複合年增長率增長。 製藥和生物技術領域的快速增長、政府對製藥和生物技術行業的支持不斷增加、慢性病的增加以及全球製藥和生物製藥公司數量的增加是推動市場增長的主要因素。

本報告對全球病毒滅活市場進行研究分析，提供市場動態、市場分析、公司概況等系統信息。

內容

第一章前言

  • 報告說明
    • 報告的目的
    • 目標
    • 主要產品
  • 市場細分
  • 調查方法
    • 第一階段 - 第二次調查
    • 第二階段 - 第一項研究
    • 第三階段 - 專家評審
    • 假設
    • 採用的方法

第 2 章執行摘要

  • 市場快照:全球病毒滅活市場
  • 全球病毒滅活市場（百萬美元）（2021 年）:按方法
  • 全球病毒滅活市場（百萬美元）（2021 年）:按產品分類
  • 全球病毒滅活市場（百萬美元）（2021 年）:按應用分類
  • 全球病毒滅活市場（百萬美元）（2021 年）:按最終用戶分類
  • 全球病毒滅活市場（百萬美元）（2021 年）:按地區
  • 有吸引力的投資提案（2021 年）:按地區

第 3 章病毒滅活市場:競爭分析

  • 領先的病毒滅活市場供應商的市場定位
  • 供應商在病毒滅活市場採用的策略
  • 主要行業戰略
  • 分層分析:2021 年和 2030 年的比較

第 4 章病毒滅活市場:宏觀分析和市場動態

  • 介紹
  • 世界病毒滅活市場價值（百萬美元）（2020-2030 年）
  • 市場動態
    • 市場驅動力
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章病毒滅活市場，百萬美元 (2020-2030):按方法

  • 市場概覽
  • 增長和收益分析:2021 年和 2030 年的比較
  • 市場細分
    • 溶劑清洗法
    • 滅菌
    • 其他病毒滅活方法

第 6 章病毒滅活市場，百萬美元（2020-2030 年）:按產品分類

  • 市場概覽
  • 增長和收益分析:2021 年和 2030 年的比較
  • 市場細分
    • 試劑盒和試劑
    • 服務
    • 病毒滅活系統及配件

第 7 章病毒滅活市場，百萬美元（2020-2030 年）:按應用

  • 市場概覽
  • 增長和收益分析:2021 年和 2030 年的比較
  • 市場細分
    • 血液和血液製品
    • 細胞和基因治療產品
    • 幹細胞產品
    • 組織和組織產品
    • 疫苗和藥物

第 8 章病毒滅活市場，百萬美元（2020-2030 年）:按最終用戶分類

  • 市場概覽
  • 增長和收益分析:2021 年和 2030 年的比較
  • 市場細分
    • 製藥和生物技術公司
    • 委託研究機構
    • 學術研究所
    • 其他最終用戶

第 9 章北美病毒滅活市場，美元（百萬）（2020-2030）

第 10 章英國和歐盟病毒滅活市場，百萬美元 (2020-2030)

第 11 章亞太病毒滅活市場，美元（百萬）（2020-2030）

第 12 章拉丁美洲病毒滅活市場，美元（百萬）（2020-2030）

第 13 章中東和非洲病毒滅活市場，百萬美元（2020-2030 年）

第14章公司簡介

  • Merck & Co., Inc.
  • PARKER HANNIFIN CORP
  • Sartorius AG
  • Texcell
  • Cytiva
  • Danaher.
  • SGS SA
  • Charles River Laboratories.
  • Cleancells
  • Rad Source Technologies
  • WuXiAppTec
  • GENERAL ELECTRIC COMPANY
  • Sigma-Aldrich Co.
  • Thermo Fisher Scientific Inc.
  • Macopharma
  • Cerus Corporation
  • 他
Product Code: 139430-01-23

The global viral inactivation market reached USD 550 Million in 2021 and is expected to register a CAGR of 12.5% during the forecast period of 2022 to 2030. Regulatory authorities require viral inactivation testing for investigational new drug (IND) submission, and it is crucial for the process development of biologicals, such as tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, vaccines, and therapeutics. Rapid growth in the pharmaceutical and biotechnology sectors and a strong trend of R&D spending in the life sciences industry are the primary market drivers. Increasing government support for the pharmaceutical and biotechnology industries, as well as an increase in the prevalence of chronic diseases, will also contribute to the expansion of this industry. The rise in the number of pharmaceutical and biopharmaceutical companies worldwide, the rise in investment in the life sciences sector, the rise in the number of drug launches and approvals, and the rise in government funding for the development of the pharmaceutical and biopharmaceutical industries are among the major factors driving the market growth. The global growth in chronic diseases such as cancer, diabetes, autoimmune disorders, and other illnesses has contributed to an increase in healthcare costs. An increase in healthcare expenditures is required primarily to conceive and develop new and improved medications to combat the escalation of these diseases. Increasing R&D innovation, medication discoveries, and FDA approvals that culminate in the marketing of new drugs are driving market expansion.

Rising Incidence of Chronic Diseases

A rise in the prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, as well as an increase in healthcare spending, are the primary drivers driving the growth of the viral inactivation market. In 2020, the 5-year prevalence of all types of malignancies in both sexes in Africa is projected to be 2,166,740. In addition, it has been stated that, of these cases, 1,298,101 were documented in females and 868,639 in males of all ages. Such a high incidence of cancer is driving market expansion over the projection period. Additionally, the same source indicated that the 5-year prevalence of cancer cases in Saudi Arabia is approximately 82,640 cases of all types of cancer in both sexes, with 39,241 male cases and 43,399 female cases reported in 2020. Increasing approvals from the Food and Medication Administration for drug candidates are also anticipated to fuel the expansion of the market under study. According to data published in Mid-Year Review: New Drug Approvals in June 2021, the United States Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) approved 26 New Molecular Entities (NMEs) at the halfway point of 2021 (as of June 28, 2021), which was comparable to the approval rate for the entire year of 2020, which was 53 NMEs. Except for 2018, when 59 NMEs were given, the number of NMEs approved in 2020 was the second highest in the previous decade, trailing only 2018's total of 59. Increasing FDA approvals will raise research and development activities, which in turn will necessitate toxicological screening studies. These studies are anticipated to promote the adoption of viral inactivation technologies, hence driving the expansion of this market. Thus, the aforementioned elements are anticipated to stimulate market expansion.

Kits and Reagents Dominate the Product Market

The market is segmented by product into kits & reagents, systems, and services. Due to the continued use of kits and reagents by pharmaceutical and biopharmaceutical businesses, kits and reagents held the greatest market share in 2021. Due to the simplicity of management and specialized services provided by service-providing organizations, the services industry is expected to grow at the highest rate. With a surge in the number of pharmaceutical and biopharmaceutical businesses and spending on research and development for new medication development, the demand for kits and reagents has skyrocketed. Due to the rising use of consumables, kits, and reagents in a variety of end-use settings, this was the largest market sector for the product.

Vaccines and Therapeutics Segment to Dominate the Application Market

The viral inactivation market is categorized by application into vaccines and treatments, stem cell products, blood and blood tissue products, tissue and tissue products, and cellular and gene therapy products. The vaccine and therapeutics sector held the largest revenue share in 2021. The highest market revenue is attributable to higher incidences and the enormous economic burden of chronic diseases such as Cancer, which demanded inactivated vaccines and increased government support for pharmaceutical and biotechnology industries to invest in the research and development of novel therapeutics. In 2020, the International Agency for Research on Cancer (Globocan) reported that 495,773 new cases of pancreatic cancer were detected worldwide. According to GLOBOCAN 2020 data, the incidence of new pancreatic cancer cases in countries with a very high HDI (Human Development Index) was 275,036, followed by 187,205 in countries with a high HDI. There were 24,705 and 8,586 cases in nations with medium and low HDI, respectively. Similarly, rising activities by industry participants are anticipated to support market expansion. Prestige Biopharma (PBP), a Singapore-based biopharmaceutical business, announced in March 2022 that its Innovative Discovery Centre (IDC) is being constructed in Busan, South Korea. The IDC will guide PBP's future vision through initiatives such as the development of antibody therapies, including treatments for pancreatic cancer, and cutting-edge vaccination technology. In addition, there are efforts to create pancreatic cancer-treating vaccinations. In October 2020, experts from the Francis Crick Institute in London, United Kingdom, revealed an experimental vaccination based on immunotherapy that targets the KRAS gene, which is implicated in the development of numerous types of cancer. Thus, the aforementioned elements are anticipated to stimulate market expansion.

Pharma and BioPharma Segment Dominate the End User Segment

Based on end-use, the viral inactivation market is segmented into pharmaceutical and biopharmaceutical firms, contract research organizations (CROs), academic and research institutions, and others. In addition, laboratories and blood banks are also considered to be medical suppliers. Due to the rising use of these items in medication development and drug manufacturing, the pharmaceutical and biopharmaceutical industries held the highest market share in 2021. In the past few decades, the pharmaceutical and biopharmaceutical industries have experienced tremendous expansion. The number of new pharmaceuticals has increased as a result of a rise in funding for the discovery of alternative therapies. With the emergence of biologics and other cellular and gene therapy products, pharmaceutical and biopharmaceutical companies have increased their use of viral inactivation products. The product's safety for human usage is ensured by stringent regulatory criteria for therapeutic agents. Biopharmaceutical businesses frequently use strategies such as solvent detergent, low pH, pasteurization, and other measures to ensure the safety of their products. Companies use single-use systems or bioreactors to carry out these treatments and inactivate viruses.

North America Remains as the Global Leader

Throughout the forecast period, North America held the dominant position in 2021. The U.S. remained the largest revenue share in North America. In addition, the advanced healthcare infrastructure, the presence of large pharmaceutical and biopharmaceutical businesses, and the significant healthcare R&D expenditures by the government and companies in the United States are expected to drive the North American market. According to ClinicalTrial.gov, Canadian pharmaceutical companies and research institutions had robust R&D pipelines in 2021, with 5,659 new studies in various stages of evaluation, 1,397 (24%) of which were in Phase III clinical trials approved by the food and drug administration (FDA) or EMA (European Medicines Agency), representing a broad range of therapeutic areas; this condition will stimulate market growth in the country. The Plan to Mobilize Science in 2020 of the Canadian government contains USD 192 million for coronavirus research and medical countermeasures, as well as up to USD 56 million for clinical trials of a COVID-related vaccine candidate from Variations Biotechnology Inc. Mexico plans to release its National Pharmaceutical Policy in April 2022, which will address a variety of supply chain and regulatory challenges, and the framework collaboration agreements signed by Mexico will strengthen scientific research and foster pharmaceutical innovation, which will lead to an increase in the number of drug discoveries in the country, thereby increasing the country's economy. In addition, with additional funding from Michigan Drug Discovery in 2021, researchers from throughout the University of Michigan are investigating methods to treat pain, cancer, and infection. The market is driven by the fact that four of the five studies will seek novel physiologically active chemicals that can be used to target essential drug discovery targets. As a result of the aforementioned factors, it is anticipated that the studied market would expand more rapidly throughout the forecast period.

Market Moving towards Consolidation during the Forecast Period

The market for viral inactivation is moderately concentrated and competitive, with many significant competitors. In terms of market share, a small number of market leaders are now utilizing a variety of development methods to dominate the industry. Some important firms are consolidating their global market positions through strategic acquisitions and mergers. In addition, it is anticipated that new players will enter the market with unique product pipelines and ongoing technological advancements that will raise market revenue throughout the projection period. The bulk of participants is focusing on new product development. The market is characterized by numerous mergers and acquisitions, resulting in a high degree of market consolidation. The major players in this market include Merck & Co., Inc., PARKER HANNIFIN CORP, Sartorius AG, Texcell, Cytiva, Danaher., SGS SA, Charles River Laboratories., Cleancells, Rad Source Technologies, WuXiAppTec, GENERAL ELECTRIC COMPANY, Sigma-Aldrich Co., Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, and others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Viral Inactivation market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Viral Inactivation market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Method

Solvent Detergent Method

Pasteurization

Other Viral Inactivation Method

Product

Kits and Reagents

Services

Viral Inactivation Systems and Accessories

Application

Blood & Blood Products

Cellular & Gene Therapy Products

Stem Cell Products

Tissue & Tissue Products

Vaccines and Therapeutics

End User

Pharmaceutical and Biotechnology Companies

Contract Research Organizations

Academic Research Institutes

Other End Users

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Viral Inactivation market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Viral Inactivation market?

Which is the largest regional market for Viral Inactivation market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Viral Inactivation market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Inactivation market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Viral Inactivation Market
  • 2.2. Global Viral Inactivation Market, By Method, 2021 (US$ Million)
  • 2.3. Global Viral Inactivation Market, By Product, 2021 (US$ Million)
  • 2.4. Global Viral Inactivation Market, By Application, 2021 (US$ Million)
  • 2.5. Global Viral Inactivation Market, By End User, 2021 (US$ Million)
  • 2.6. Global Viral Inactivation Market, By Geography, 2021 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2021

3. Viral Inactivation Market: Competitive Analysis

  • 3.1. Market Positioning of Key Viral Inactivation Market Vendors
  • 3.2. Strategies Adopted by Viral Inactivation Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Viral Inactivation Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Viral Inactivation Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Viral Inactivation Market: By Method, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Solvent Detergent Method
    • 5.3.2. Pasteurization
    • 5.3.3. Other Viral Inactivation Method

6. Viral Inactivation Market: By Product, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Kits and Reagents
    • 6.3.2. Services
    • 6.3.3. Viral Inactivation Systems and Accessories

7. Viral Inactivation Market: By Application, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 7.3. Market Segmentation
    • 7.3.1. Blood & Blood Products
    • 7.3.2. Cellular & Gene Therapy Products
    • 7.3.3. Stem Cell Products
    • 7.3.4. Tissue & Tissue Products
    • 7.3.5. Vaccines and Therapeutics

8. Viral Inactivation Market: By End User, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 8.3. Market Segmentation
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. Contract Research Organizations
    • 8.3.3. Academic Research Institutes
    • 8.3.4. Other End Users

9. North America Viral Inactivation Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
  • 9.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
  • 9.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
  • 9.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
  • 9.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 9.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 9.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 9.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 9.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 9.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 9.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 9.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 9.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 9.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)

10. UK and European Union Viral Inactivation Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
  • 10.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
  • 10.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
  • 10.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
  • 10.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 10.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 10.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 10.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 10.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 10.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 10.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 10.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 10.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 10.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 10.6.1.4.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 10.6.1.4.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 10.6.1.4.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 10.6.1.5.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 10.6.1.5.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 10.6.1.5.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 10.6.1.6.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 10.6.1.6.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 10.6.1.6.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)

11. Asia Pacific Viral Inactivation Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
  • 11.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
  • 11.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
  • 11.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
  • 11.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 11.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 11.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 11.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 11.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 11.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 11.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 11.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 11.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 11.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 11.6.1.4.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 11.6.1.4.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 11.6.1.4.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 11.6.1.5.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 11.6.1.5.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 11.6.1.5.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 11.6.1.6.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 11.6.1.6.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 11.6.1.6.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)

12. Latin America Viral Inactivation Market, 2020-2030, USD (Million)

  • 12.1. Market Overview
  • 12.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
  • 12.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
  • 12.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
  • 12.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
  • 12.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 12.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 12.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 12.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 12.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 12.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 12.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 12.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 12.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 12.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)

13. Middle East and Africa Viral Inactivation Market, 2020-2030, USD (Million)

  • 13.1. Market Overview
  • 13.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
  • 13.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
  • 13.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
  • 13.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
  • 13.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 13.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 13.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 13.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 13.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 13.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 13.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
        • 13.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
        • 13.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
        • 13.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)

14. Company Profile

  • 14.1. Merck & Co., Inc.
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. PARKER HANNIFIN CORP
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. Sartorius AG
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Texcell
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. Cytiva
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Danaher.
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. SGS SA
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. Charles River Laboratories.
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
  • 14.9. Cleancells
    • 14.9.1. Company Overview
    • 14.9.2. Financial Performance
    • 14.9.3. Product Portfolio
    • 14.9.4. Strategic Initiatives
  • 14.10. Rad Source Technologies
    • 14.10.1. Company Overview
    • 14.10.2. Financial Performance
    • 14.10.3. Product Portfolio
    • 14.10.4. Strategic Initiatives
  • 14.11. WuXiAppTec
    • 14.11.1. Company Overview
    • 14.11.2. Financial Performance
    • 14.11.3. Product Portfolio
    • 14.11.4. Strategic Initiatives
  • 14.12. GENERAL ELECTRIC COMPANY
    • 14.12.1. Company Overview
    • 14.12.2. Financial Performance
    • 14.12.3. Product Portfolio
    • 14.12.4. Strategic Initiatives
  • 14.13. Sigma-Aldrich Co.
    • 14.13.1. Company Overview
    • 14.13.2. Financial Performance
    • 14.13.3. Product Portfolio
    • 14.13.4. Strategic Initiatives
  • 14.14. Thermo Fisher Scientific Inc.
    • 14.14.1. Company Overview
    • 14.14.2. Financial Performance
    • 14.14.3. Product Portfolio
    • 14.14.4. Strategic Initiatives
  • 14.15. Macopharma
    • 14.15.1. Company Overview
    • 14.15.2. Financial Performance
    • 14.15.3. Product Portfolio
    • 14.15.4. Strategic Initiatives
  • 14.16. Cerus Corporation
    • 14.16.1. Company Overview
    • 14.16.2. Financial Performance
    • 14.16.3. Product Portfolio
    • 14.16.4. Strategic Initiatives
  • 14.17. Others
    • 14.17.1. Company Overview
    • 14.17.2. Financial Performance
    • 14.17.3. Product Portfolio
    • 14.17.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 2 Global Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 3 Global Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 4 Global Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 5 North America Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 6 North America Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 7 North America Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 8 North America Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 9 U.S. Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 10 U.S. Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 11 U.S. Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 12 U.S. Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 13 Canada Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 14 Canada Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 15 Canada Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 16 Canada Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 17 Rest of North America Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 18 Rest of North America Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 19 Rest of North America Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 20 Rest of North America Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 21 UK and European Union Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 22 UK and European Union Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 23 UK and European Union Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 24 UK and European Union Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 25 UK Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 26 UK Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 27 UK Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 28 UK Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 29 Germany Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 30 Germany Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 31 Germany Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 32 Germany Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 33 Spain Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 34 Spain Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 35 Spain Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 36 Spain Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 37 Italy Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 38 Italy Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 39 Italy Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 40 Italy Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 41 France Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 42 France Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 43 France Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 44 France Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 45 Rest of Europe Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 46 Rest of Europe Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 47 Rest of Europe Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 48 Rest of Europe Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 49 Asia Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 50 Asia Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 51 Asia Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 52 Asia Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 53 China Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 54 China Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 55 China Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 56 China Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 57 Japan Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 58 Japan Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 59 Japan Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 60 Japan Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 61 India Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 62 India Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 63 India Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 64 India Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 65 Australia Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 66 Australia Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 67 Australia Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 68 Australia Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 69 South Korea Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 70 South Korea Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 71 South Korea Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 72 South Korea Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 73 Latin America Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 74 Latin America Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 75 Latin America Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 76 Latin America Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 77 Brazil Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 78 Brazil Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 79 Brazil Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 80 Brazil Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 81 Mexico Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 82 Mexico Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 83 Mexico Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 84 Mexico Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 85 Rest of Latin America Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 86 Rest of Latin America Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 87 Rest of Latin America Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 88 Rest of Latin America Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 89 Middle East and Africa Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 90 Middle East and Africa Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 91 Middle East and Africa Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 92 Middle East and Africa Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 93 GCC Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 94 GCC Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 95 GCC Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 96 GCC Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 97 Africa Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 98 Africa Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 99 Africa Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 100 Africa Viral Inactivation Market By End User, 2020-2030, USD (Million)
  • TABLE 101 Rest of Middle East and Africa Viral Inactivation Market By Method, 2020-2030, USD (Million)
  • TABLE 102 Rest of Middle East and Africa Viral Inactivation Market By Product, 2020-2030, USD (Million)
  • TABLE 103 Rest of Middle East and Africa Viral Inactivation Market By Application, 2020-2030, USD (Million)
  • TABLE 104 Rest of Middle East and Africa Viral Inactivation Market By End User, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Viral Inactivation Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Viral Inactivation Market: Quality Assurance
  • FIG. 5 Global Viral Inactivation Market, By Method, 2021
  • FIG. 6 Global Viral Inactivation Market, By Product, 2021
  • FIG. 7 Global Viral Inactivation Market, By Application, 2021
  • FIG. 8 Global Viral Inactivation Market, By End User, 2021
  • FIG. 9 Global Viral Inactivation Market, By Geography, 2021
  • FIG. 10 Market Geographical Opportunity Matrix - Global Viral Inactivation Market, 2021
  • FIG. 11 Market Positioning of Key Viral Inactivation Market Players, 2021
  • FIG. 12 Global Viral Inactivation Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 13 Global Viral Inactivation Market, By Method, 2021 Vs 2030, %
  • FIG. 14 Global Viral Inactivation Market, By Product, 2021 Vs 2030, %
  • FIG. 15 Global Viral Inactivation Market, By Application, 2021 Vs 2030, %
  • FIG. 16 Global Viral Inactivation Market, By End User, 2021 Vs 2030, %
  • FIG. 17 U.S. Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 18 Canada Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of North America Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 20 UK Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 21 Germany Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 22 Spain Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 23 Italy Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 24 France Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Europe Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 26 China Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 27 Japan Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 28 India Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 29 Australia Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 30 South Korea Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Asia Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 32 Brazil Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 33 Mexico Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 34 Rest of Latin America Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 35 GCC Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 36 Africa Viral Inactivation Market (US$ Million), 2020 - 2030
  • FIG. 37 Rest of Middle East and Africa Viral Inactivation Market (US$ Million), 2020 - 2030